Opportunity Description
Director, Drug Product, Technical Operations
Location: Princeton, NJ or Oxford, UK onsite.
Join to apply for the Director, Drug Product, Technical Operations role at Summit Therapeutics, Inc.
About Summit
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:
- HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally adva...
Ready to Apply?
Submit your application for Director, Drug Product, Technical Operations at Summit Therapeutics, Inc.
Apply for this Position